Bone mineral density in XXXX : assessment using dual x-ray absorptiometry.

@entity1 @entity6017 @entity66 @entity171 @entity170 @entity3814 @entity8817 @entity79 @entity2331
OBJECTIVE: To determine the @entity79 ( @entity79 ) status of our @entity8817 ( @entity6017 ) population and to compare the frequency of @entity2331 in @entity1 with @entity66 requiring corticosteroids with that in @entity1 with inactive disease who are not receiving corticosteroids. METHODS: Medical charts of all @entity1 diagnosed as having juvenile @entity6017 at our institution between 1989 and 1999 were reviewed for demographic and clinical data, including disease activity and duration of corticosteroid therapy. @entity79 measurements of the lumbar spine (L1-L4) were performed using dual x-ray absorptiometry (DXA). Z scores were calculated from the @entity79 data for comparison with published normative data. RESULTS: A total of 15 @entity1 were assessed: 10 with @entity66 , and 5 with inactive disease who had not taken corticosteroids for an average of 6.0 years (range 3.4-8.1 years). Baseline @entity79 measurements demonstrated @entity2331 or @entity170 in the majority of @entity1 , including 6 of the 10 @entity1 with @entity66 and 4 of the 5 @entity1 whose disease was in remission. Fourteen @entity1 had serial @entity79 measurements. Persistent or worsening @entity2331 was documented in all @entity1 who had ongoing @entity66 , except for 3 @entity1 who had been treated with @entity171 because of @entity3814 . CONCLUSION: @entity2331 is common in @entity1 with juvenile @entity6017 , and it usually worsens with @entity66 . It can persist for many years after the disease enters remission. Bisphosphonates appeared to beneficially affect bone mineralization in our @entity1 . Treatment to prevent the long-term complications of @entity170 in @entity1 with juvenile @entity6017 should be considered and requires further study.
